Application of a physiologically based model incorporating drug-specific PK modules to support optimization of GLP-1 receptor agonist combination therapies for type 2 diabetes
Presented by Rosa at the American Association of Pharmaceutical Scientists (AAPS), 2013
Physiological model to investigate and prioritize targets for psoriasis
Presented by Stiefel and Rosa at American Conference on Pharmacometrics (ACoP), 2013, and at American Association of Pharmaceutical Scientists (AAPS) 2013
Mechanistic and quantitative physiological models for the evaluation and prioritization of dermatology disease targets
Presented by Stiefel and Rosa at American Society for Clinical Pharmacology and Therapeutics (ASCPT), 2013
Virtual Combination Therapy in Virtual NSCLC Tumor Cells Supports Strategic Development and Treatment Decisions
Presented by Rosa at the Keystone Symposia, Cancer and Metabolism, 2013
Using Formal Qualitative Modeling in Drug Development
Presented by Rosa at the American Conference on Pharmacometrics (ACoP), 2013
Application of Mechanistic Physiological Modeling in the Drug Development Process – Overview and Case Studies
Presented by Rosa at the 28th Japanese Society for the Study of Xenobiotics (JSSX) Annual Meeting on Drug Metabolism and Pharmacokinetics, 2013
Accomplishments and Challenges in Systems Pharmacology
Presented by Rosa at the Hanson Wade Integrating Pharmacometrics Summit, 2013
Models and Their Utility in the Drug Development Process
Presented by Rosa at the American Association of Pharmaceutical Scientists (AAPS) Bay Area Development Group (BADG), 2013
